Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.36 |
| ▸ | NUDT1 | P36639 | 5/20 | 0.35 |
| ▸ | MAP4K4 | O95819 | 4/20 | 0.34 |
| ▸ | PTPN11 | Q06124 | 3/20 | 0.33 |
| ▸ | ERN1 | O75460 | 1/20 | 0.33 |
| ▸ | BRAF | P15056 | 1/20 | 0.33 |
| ▸ | RET | P07949 | 1/20 | 0.32 |
| ▸ | ABL1 | P00519 | 1/20 | 0.32 |
| ▸ | SRC | P12931 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31727873 | 0.74 | SMN1; SMN2 (0.40) | DGAT1NUDT1MAP4K4PTPN11 | |
| SCHEMBL31728633 | 0.74 | MAP4K4 (0.41) | DGAT1NUDT1MAP4K4 | |
| SCHEMBL31728080 | 0.73 | NOTUM (0.39) | DGAT1NUDT1 | |
| SCHEMBL31729125 | 0.72 | DGAT1 (0.38) | DGAT1PIK3CDNUDT1PTPN11 | |
| SCHEMBL31728863 | 0.71 | DGAT1 (0.39) | DGAT1NUDT1MAP4K4PTPN11 | |
| SCHEMBL31727998 | 0.70 | MAP4K4 (0.49) | DGAT1MAP4K4PTPN11 | |
| SCHEMBL31729239 | 0.69 | CNR2 (0.53) | DGAT1PIK3CDPTPN11 | |
| SCHEMBL31728894 | 0.69 | PTPN11 (0.41) | DGAT1NUDT1PTPN11 | |
| SCHEMBL31728779 | 0.69 | NOTUM (0.43) | DGAT1NUDT1 | |
| SCHEMBL31728623 | 0.65 | SMN1; SMN2 (0.39) | PIK3CDNUDT1MAP4K4RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025235874-A1 | HETEROCYCLICS AS EGFR INHIBITORS | SCHRÖDINGER, INC. (US) | 2025-11-13 | — | — | WO | disclosed |